Vaniprevir
Подписчиков: 0, рейтинг: 0
|
| |
| Names | |
|---|---|
|
IUPAC name
(1R,21S,24S)-21-tert-Butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
| |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.207.830 |
| EC Number |
|
| KEGG | |
|
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C38H55N5O9S | |
| Molar mass | 757.94 g·mol−1 |
| Appearance | White powder |
| Hazards | |
| GHS labelling: | |
|
|
|
| Warning | |
| H373 | |
| P260, P314, P501 | |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
| Hepatitis C |
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis D | |||||||||
| Picornavirus | |||||||||
| Anti-influenza agents | |||||||||
| Multiple/general |
|
||||||||
| |||||||||